103 related articles for article (PubMed ID: 2319129)
1. The use of peptide analogs with improved stability and MHC binding capacity to inhibit antigen presentation in vitro and in vivo.
Lamont AG; Powell MF; Colón SM; Miles C; Grey HM; Sette A
J Immunol; 1990 Apr; 144(7):2493-8. PubMed ID: 2319129
[TBL] [Abstract][Full Text] [Related]
2. Failure to demonstrate long-lived MHC saturation both in vitro and in vivo. Implications for therapeutic potential of MHC-blocking peptides.
Ishioka GY; Adorini L; Guery JC; Gaeta FC; LaFond R; Alexander J; Powell MF; Sette A; Grey HM
J Immunol; 1994 May; 152(9):4310-9. PubMed ID: 8157954
[TBL] [Abstract][Full Text] [Related]
3. Effect of conformational propensity of peptide antigens in their interaction with MHC class II molecules. Failure to document the importance of regular secondary structures.
Sette A; Lamont A; Buus S; Colon SM; Miles C; Grey HM
J Immunol; 1989 Aug; 143(4):1268-73. PubMed ID: 2787362
[TBL] [Abstract][Full Text] [Related]
4. Primary in vivo responses to ovalbumin. Probing the predictive value of the Kb binding motif.
Lipford GB; Hoffman M; Wagner H; Heeg K
J Immunol; 1993 Feb; 150(4):1212-22. PubMed ID: 7679422
[TBL] [Abstract][Full Text] [Related]
5. Fine specificity of murine class II-restricted T cell clones for synthetic peptides of influenza virus hemagglutinin. Heterogeneity of antigen interaction with the T cell and the Ia molecule.
Mills KH; Burt DS; Skehel JJ; Thomas DB
J Immunol; 1988 Jun; 140(12):4083-90. PubMed ID: 2453566
[TBL] [Abstract][Full Text] [Related]
6. A novel approach to the generation of high affinity class II-binding peptides.
Sette A; Sidney J; Albertson M; Miles C; Colón SM; Pedrazzini T; Lamont AG; Grey HM
J Immunol; 1990 Sep; 145(6):1809-13. PubMed ID: 1975260
[TBL] [Abstract][Full Text] [Related]
7. I-Ak polymorphisms define a functionally dominant region for the presentation of hen egg lysozyme peptides.
Rosloniec EF; Vitez LJ; Beck BN; Buerstedde JM; McKean DJ; Landais D; Benoist C; Mathis D; Freed JH
J Immunol; 1989 Jul; 143(1):50-8. PubMed ID: 2786533
[TBL] [Abstract][Full Text] [Related]
8. Peptides corresponding to CD4-interacting regions of murine MHC class II molecules modulate immune responses of CD4+ T lymphocytes in vitro and in vivo.
Shen X; Hu B; McPhie P; Wu X; Fox A; Germain RN; König R
J Immunol; 1996 Jul; 157(1):87-100. PubMed ID: 8683160
[TBL] [Abstract][Full Text] [Related]
9. Class II MHC/peptide complexes are released from APC and are acquired by T cell responders during specific antigen recognition.
Patel DM; Arnold PY; White GA; Nardella JP; Mannie MD
J Immunol; 1999 Nov; 163(10):5201-10. PubMed ID: 10553040
[TBL] [Abstract][Full Text] [Related]
10. Specific proteolytic cleavages limit the diversity of the pool of peptides available to MHC class I molecules in living cells.
Serwold T; Shastri N
J Immunol; 1999 Apr; 162(8):4712-9. PubMed ID: 10202012
[TBL] [Abstract][Full Text] [Related]
11. Biological activity and therapeutic potential of homologs of an Ii peptide which regulates antigenic peptide binding to cell surface MHC class II molecules.
Adams S; Albericio F; Alsina J; Smith ER; Humphreys RE
Arzneimittelforschung; 1997 Sep; 47(9):1069-77. PubMed ID: 9342425
[TBL] [Abstract][Full Text] [Related]
12. Up-regulation of the MHC class II molecules on B cells by peptide ligands.
Agrawal B; Fraga E; Kane K; Singh B
J Immunol; 1994 Feb; 152(3):965-75. PubMed ID: 8301149
[TBL] [Abstract][Full Text] [Related]
13. Use of global amino acid replacements to define the requirements for MHC binding and T cell recognition of moth cytochrome c (93-103).
Reay PA; Kantor RM; Davis MM
J Immunol; 1994 Apr; 152(8):3946-57. PubMed ID: 7511662
[TBL] [Abstract][Full Text] [Related]
14. Molecular analysis of the same HIV peptide functionally binding to both a class I and a class II MHC molecule.
Takeshita T; Takahashi H; Kozlowski S; Ahlers JD; Pendleton CD; Moore RL; Nakagawa Y; Yokomuro K; Fox BS; Margulies DH
J Immunol; 1995 Feb; 154(4):1973-86. PubMed ID: 7530749
[TBL] [Abstract][Full Text] [Related]
15. Peptide affinity for MHC influences the phenotype of CD8(+) T cells primed in vivo.
Ma H; Kapp JA
Cell Immunol; 2001 Nov; 214(1):89-96. PubMed ID: 11902833
[TBL] [Abstract][Full Text] [Related]
16. Class I-restricted presentation occurs without internalization or processing of exogenous antigenic peptides.
Hosken NA; Bevan MJ; Carbone FR
J Immunol; 1989 Feb; 142(4):1079-83. PubMed ID: 2492575
[TBL] [Abstract][Full Text] [Related]
17. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
De Veerman M; Heirman C; Van Meirvenne S; Devos S; Corthals J; Moser M; Thielemans K
J Immunol; 1999 Jan; 162(1):144-51. PubMed ID: 9886380
[TBL] [Abstract][Full Text] [Related]
18. Nature of the ligand recognized by a hapten- and carrier-specific, MHC-restricted T cell receptor.
Nalefski EA; Rao A
J Immunol; 1993 May; 150(9):3806-16. PubMed ID: 7682584
[TBL] [Abstract][Full Text] [Related]
19. Diversity in MHC class II ovalbumin T cell epitopes generated by distinct proteases.
Vidard L; Rock KL; Benacerraf B
J Immunol; 1992 Jul; 149(2):498-504. PubMed ID: 1378066
[TBL] [Abstract][Full Text] [Related]
20. Modulation of antigen presentation and class II expression by a class II-associated invariant chain peptide.
Zechel MA; Chaturvedi P; Lee-Chan EC; Rider BJ; Singh B
J Immunol; 1996 Jun; 156(11):4232-9. PubMed ID: 8666792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
